Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 34,382,284
- Total 13F shares
- 79,917
- Share change
- +79,917
- Total reported value
- $413,466
- Price per share
- $5.15
- Number of holders
- 7
- Value change
- +$413,466
- Number of buys
- 7
Quarterly Holders Quick Answers
What is CUSIP 87975F104?
CUSIP 87975F104 identifies TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q2 2024
Recent filing periods for CUSIP 87975F104:
Top shareholders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Christopher Chapman MD |
3/4/5
|
CEO & Chairman, Director |
—
class O/S missing
|
975,610
|
$6,048,782 | — | 08 Feb 2024 | |
| Craig Eagle |
3/4/5
|
Director |
—
class O/S missing
|
487,805
|
$3,024,391 | — | 08 Feb 2024 | |
| Nathen Fuentes |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
101,134
|
$627,031 | — | 08 Feb 2024 | |
| Bradley Kroenig |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Hugh Mccoll III |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Talhia Tuck |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 |
Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) as of Q1 2024
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2025 Across Filers
| Investor | Q4 2025 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.